KWKirsten WhitePhDSlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018B/F/TAF in treatment-naïve HIV-1 and HIV-1 RNA suppressed switch patients- Kirsten White, MD, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018Acute hepatitis A to E, diagnosis and management - Thomas Berg, MDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018Evaluation of pre-treatment risk factors associated with failure in HCVinfected patients naive to direct acting antivirals: particular focus on natural resistance- Silvia BarbalisciaView Slideset
SFSlim FouratiMD, PhDSlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018Selection of fitness-associated substitutions in patients failing NS5A inhibitors based therapy : analysis of HCV full-length genome deep sequencing by means of shotgun metagenomics- Slim FouratiView Slideset
FCFrancesca Ceccherini-SilbersteinPhDSlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018Management of hepatitis C therapy failures - virological perspective- Francesca Ceccherini– Silberstein, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018Management of hepatitis C therapy failures - clinical perspective- Sanjay Bhagani, BSc FRCPView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018Novel simplified bioinformatics for NGS data analysis- Marc Noguera-Julian, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018Mutations in the 3’-polypurine tract of HIV-1 point to a new integrase strand transfer inhibitor (INSTI) resistance mechanism in vivo- Jeroen van KampenView Slideset
MSMaria SantoroPhDSlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018Factors associated with virological response and resistance profile in HIV-1 infected patients starting first-line integrase inhibitors based regimen in clinical settings- Maria SantoroView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018Dynamics of therapy options for HIV-1 infected patients with historical multi-drug resistance (MDR), based on deep-sequencing of proviral DNA – First Results from the LOWER Study- Alexander ThielenView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018Resistance mutations to different classes of antiretroviral agents predict virological failure in HIV+ patients with low level viremia: a retrospective study from the ARCA cohort- Francesca LombardiView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2018A new wild-type HIV in the era of transmitted drug resistance- Kristof Theys, PhDView Slideset
